Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal

 
• By Jo Shorthouse

Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it develop immunotherapies directed against three proprietary targets, with the option of two more.

Keys
Genmab may be unlocking the door to its post-Darzalex future

More from Anticancer

More from Therapy Areas